Company intelligence / Profile preview
Ultragenyx Pharmaceutical Inc.
Novato, California, United Statesultragenyx.com ↗
- Ownership
- Public · RARE
- Employees
- ~651
- Development stage
- Commercial
01
Overview
Ultragenyx has four approved products: Crysvita (burosumab) for XLH and tumor-induced osteomalacia, Mepsevii (vestronidase alfa) for MPS VII, Dojolvi (triheptanoin) for LC-FAOD, and Evkeeza (evinacumab-dgnb) for HoFH. The company reported preliminary 2024 total revenue of $555-560 million and expects 2025 revenue of $640-670 million. Key late-stage programs include UX143 (setrusumab) for osteogenesis imperfecta with a Phase 3 second interim analysis expected mid-2025, and GTX-102 for Angelman syndrome with Phase 3 enrollment expected to complete in second half of 2025.[7][9]
- Therapeutic areas
- Metabolic DisordersEndocrinologyRare DiseasesCardiovascularNeurology
- Modalities
- Biologicssmall moleculesgene therapiesantisense oligonucleotides (ASO)mRNA therapeutics[7]
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
Request access →03
Partnerships
GeneTxKyowa Hakko KirinMereo BiopharmaDaiichi SankyoRegeneron[7]
04
Financials
- Market cap
- $3.4B
- Total revenue
- $139.3M
- Enterprise value
- $2.9B
Beyond the preview
Go deeper on Ultragenyx Pharmaceutical Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ultragenyx Pharmaceutical Inc..